More specifically, the use of targeted agents in patients without a BRAF mutation has been shown to have a very poor response rate to treatment of their disease and, extrapolating from lung cancer studies, a decrease in progression-free and overall survival [20,21,22]. This evidence concerns the gene BRAF and lung carcinoma.